88 related articles for article (PubMed ID: 24869759)
1. TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug.
Gheidari F; Bakhshandeh B; Teimoori-Toolabi L; Mehrtash A; Ghadir M; Zeinali S
Anticancer Drugs; 2014 Sep; 25(8):908-16. PubMed ID: 24869759
[TBL] [Abstract][Full Text] [Related]
2. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Montazami N; Kheir Andish M; Majidi J; Yousefi M; Yousefi B; Mohamadnejad L; Shanebandi D; Estiar MA; Khaze V; Mansoori B; Baghbani E; Baradaran B
Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):98-103. PubMed ID: 26025411
[TBL] [Abstract][Full Text] [Related]
3. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy.
Kendziorra E; Ahlborn K; Spitzner M; Rave-Fränk M; Emons G; Gaedcke J; Kramer F; Wolff HA; Becker H; Beissbarth T; Ebner R; Ghadimi BM; Pukrop T; Ried T; Grade M
Carcinogenesis; 2011 Dec; 32(12):1824-31. PubMed ID: 21983179
[TBL] [Abstract][Full Text] [Related]
4. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
6. SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Planutis AK; Holcombe RF; Planoutene MV; Planoutis KS
Anticancer Drugs; 2015 Oct; 26(9):942-7. PubMed ID: 26196680
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells.
Xie J; Xiang DB; Wang H; Zhao C; Chen J; Xiong F; Li TY; Wang XL
PLoS One; 2012; 7(9):e45617. PubMed ID: 23029137
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes.
Schepeler T; Holm A; Halvey P; Nordentoft I; Lamy P; Riising EM; Christensen LL; Thorsen K; Liebler DC; Helin K; Ørntoft TF; Andersen CL
Oncogene; 2012 May; 31(22):2750-60. PubMed ID: 21963845
[TBL] [Abstract][Full Text] [Related]
9. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Gu WJ; Liu HL
Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
[TBL] [Abstract][Full Text] [Related]
10. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
11. Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.
Xiao ZY; Wu W; Eagleton N; Chen HQ; Shao J; Teng H; Liu TH; Jiang ZM; Yao HR
World J Gastroenterol; 2010 Jan; 16(1):112-8. PubMed ID: 20039457
[TBL] [Abstract][Full Text] [Related]
12. The human HECA interacts with cyclins and CDKs to antagonize Wnt-mediated proliferation and chemoresistance of head and neck cancer cells.
Dowejko A; Bauer R; Bauer K; Müller-Richter UD; Reichert TE
Exp Cell Res; 2012 Mar; 318(5):489-99. PubMed ID: 22100912
[TBL] [Abstract][Full Text] [Related]
13. Txr1: an important factor in oxaliplatin resistance in gastric cancer.
Bi J; Bai Z; Ma X; Song J; Guo Y; Zhao J; Yi X; Han S; Zhang Z
Med Oncol; 2014 Feb; 31(2):807. PubMed ID: 24362794
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
[TBL] [Abstract][Full Text] [Related]
15. Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells.
Yang C; Liu HZ; Fu ZX
Oncol Rep; 2012 Sep; 28(3):1006-12. PubMed ID: 22710431
[TBL] [Abstract][Full Text] [Related]
16. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
Hua H; Chen W; Shen L; Sheng Q; Teng L
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838
[TBL] [Abstract][Full Text] [Related]
17. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α activation under glucose deprivation plays a central role in the acquisition of anti-apoptosis in human colon cancer cells.
Nishimoto A; Kugimiya N; Hosoyama T; Enoki T; Li TS; Hamano K
Int J Oncol; 2014 Jun; 44(6):2077-84. PubMed ID: 24718784
[TBL] [Abstract][Full Text] [Related]
19. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
20. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
